Abstract 1622P
Background
KRAS mutations are found in approximately 90% of PCa, of which 1-2% are KRAS G12C. D-1553 has shown clinical activity in patients (pts) with KRAS G12C mutated non-small cell lung cancer and colorectal cancer. Here, we report preliminary data of D-1553 in KRAS G12C mutated advanced PCa.
Methods
Pts with KRAS G12C mutated advanced PCa (with no standard treatment available or refractory or intolerant to existing standard treatment) were enrolled and received D-1553 at the recommended phase II dose of 600 mg BID orally. Study endpoints included safety, pharmacokinetics (PK), and efficacy (RECIST, v1.1). Efficacy endpoints included objective response, disease control (defined as an objective response or stable disease) and progression-free survival. Safety was also assessed.
Results
As of 01 March 2023, a total of 10 pts with advanced PCa (median age 67.5 years [range 48–78]; 60% female; 70% Asian; 80%/20% ECOG PS 0/1; 100% stage IV disease at baseline; 40% with ≥ 2 prior lines of therapy [median 1]) were enrolled and treated with D-1553. At data cutoff, 5 (50%) pts remained on treatment. The median duration of treatment and follow-up were 7.15 months (range 1.22-8.94) and 8.10 (range 4.47-9.23) months, respectively. The objective response rate was 50.0% (5/10, including 1 confirmed complete response, 3 confirmed partial response [PR], and 1 unconfirmed PR) and disease control rate was 80.0% (8/10). Median progression-free survival was 8.54 (95% CI 1.25-NA) months. Treatment-related adverse events (TRAEs) of any grade occurred in 7 (70.0%) pts, with the most commonly (≥ 20%) reported as increased ALT, increased AST, decreased appetite, and diarrhoea. Grade 3 TRAEs occurred in 2 (20%) pts, including increased ALT, increased AST and increased alkaline phosphatase. There was no grade > 3 TRAEs, nor TRAEs leading to death or D-1553 permanent discontinuation.
Conclusions
D-1553 is well tolerated and has shown promising anticancer activity in pts with pre-treated KRAS G12C mutated advanced PCa. This study is ongoing, and more results will be presented at the meeting.
Clinical trial identification
NCT04585035, NCT05383898.
Editorial acknowledgement
Legal entity responsible for the study
InventisBio Co., Ltd.
Funding
InventisBio Co., Ltd.
Disclosure
S. Kondo: Financial Interests, Institutional, Speaker’s Bureau: Abbie; Financial Interests, Institutional, Research Grant: Eisai, Astellas, Incyte, AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Speaker’s Bureau: Incyte, Chugai, Eisai. X. Liu, Y. Zhang, X. Xie: Financial Interests, Personal, Full or part-time Employment: InventisBio. Z. Xiang, Z. Shi, Y. Wang, L. Zhang: Financial Interests, Personal, Full or part-time Employment: InventisBio; Financial Interests, Personal, Stocks/Shares: InventisBio. N. Yamamoto: Financial Interests, Personal, Invited Speaker: Ono, Chugai, Daiichi Sankyo, Eisai; Financial Interests, Personal, Advisory Board: Eisai, Takeda, Boehringer Ingelheim, Cimic, Chugai, Healios; Financial Interests, Institutional, Invited Speaker, Principal Investigator in industry sponsored trial: Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi Sankyo, Bayer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Takeda, Ono, Janssen Pharma, MSD, Merck, GSK, Sumitomo Dainippon, Chiome Bioscience, Otsuka; Financial Interests, Institutional, Invited Speaker, Principal investigator in industry sponsored trial: Carna Biosciences, Genmab, Shionogi, Toray; Financial Interests, Institutional, Research Grant, Principal investigator in industry sponsored trial: Rakuten Medical, InventisBio Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1665P - Prognostic impact of diabetes and antidiabetic medication in pancreatic cancer patients
Presenter: Alexander Friedrich
Session: Poster session 22
1667P - Clinical and molecular features of young onset pancreatic adenocarcinoma
Presenter: Maxime Remond
Session: Poster session 22
1668P - Prevalence and management of pancreatic ductal adenocarcinoma (PDAC) over a decade in France: A population-based study
Presenter: Léo Mas
Session: Poster session 22
1670P - Tumoral and non-tumoral thrombosis associated with pancreatic ductal adenocarcinoma (PDAC): Survival impact, assessment of predictive scales and rethrombosis
Presenter: Alejandra Cardozo
Session: Poster session 22
1671P - Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry
Presenter: Teresa Macarulla
Session: Poster session 22
1673P - Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study
Presenter: Sofie Olsson Hau
Session: Poster session 22
1674P - VILP registry of patients with metastatic pancreatic cancer treated with pegylated liposomal irinotecan plus 5-fluoroucil and leucovorin in the Czech Republic
Presenter: Stanislav Batko
Session: Poster session 22
1675P - Diagnostic performance of blood-based DNA methylation assay using epigenetic-specific peptide nucleic acid in pancreatic adenocarcinoma
Presenter: Hongsik Kim
Session: Poster session 22
1676P - Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
Presenter: Nunticha Umpawan
Session: Poster session 22